Pancreatic endocrine neoplasms: A current update on genetics and imaging

British Journal of Radiology

Volumn 85, Issue 1014, 2012, Pages 682-696

  Philips, S ^a   Shah, S N ^b   Vikram, R ^c   Verma, S ^d   Shanbhogue, A K P ^a   Prasad, Srinivasa R ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GEFITINIB; IMATINIB; NEUROFIBROMIN; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; VATALANIB;

ARTIFICIAL EMBOLISM; COMPUTER ASSISTED TOMOGRAPHY; ENDOCRINE TUMOR; GASTRINOMA; GENETICS; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREATIC ENDOCRINE NEOPLASM; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUBEROUS SCLEROSIS; VIPOMA; VON HIPPEL LINDAU DISEASE;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; VON HIPPEL-LINDAU DISEASE;

EID: 84861902469     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/85014761     Document Type: Review

References (85)

1. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, et al. High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 2008;12:1674-81 (discussion: 81-2).
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92.
3. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988;183:155-68.
4. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991;36:933-42.
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
6. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25:5609-15.
7. Yamada T AD, Kaplowitz N, Owyang C, Powell DW, Kalloo AN. Endocrine neoplasms of the pancreas. 5th edn. Oxford, UK: Blackwell; 2008.
8. Norton JA, Doppman JL, Collen MJ, Harmon JW, Maton PN, Gardner JD, et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986;204:468-79. (Pubitemid 16025363)
9. Calender A. Genetics of neuroendocrine tumours. In: Caplin M, Kvols L, eds. Handbook of neuroendocrine tumours. Bristol, UK: BioScientifica; 2006. pp. 53-79.
10. Sutliff VE, Doppman JL, Gibril F, Venzon DJ, Yu F, Serrano J, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997;15:2420-31. (Pubitemid 27251146)
11. Klöppel G, Schröder S, Heitz PU. Histopathology and immunopathology of pancreatic endocrine tumors. In: Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: recent advances in research and management. Basel, Switzerland: Karger; 1995. pp. 99-120.
12. Kloppel G, Heitz PU. Tumors of the endocrine pancreas. In: Fletcher CD, ed. Diagnostic histopathology of tumors. 2nd edn. London, UK: Churchill Livingstone; 2000. pp. 1083-98.
13. Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, et al. Pancreatic endocrine tumors: introduction. In: DeLellis DA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2004. pp. 177-82.
14. Lloyd RV, Mervak T, Schmidt K, Warner TF, Wilson BS. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 1984;8:607-14. (Pubitemid 14055019)
15. Fernandez-del Castillo C, Warshaw AL. Cystic tumors of the pancreas. Surg Clin North Am 1995;75:1001-16.
16. Perez-Montiel MD, Frankel WL, Suster S. Neuroendocrine carcinomas of the pancreas with 'rhabdoid' features. Am J Surg Pathol 2003;27:642-9. (Pubitemid 36514474)
17. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-83. (Pubitemid 27308405)
18. Calender AMC, Komminoth P, Scoazec JY, Sweet KM, Teh BT, eds. Multiple endocrine neoplasia type 1. Lyon, France: IARC; 2004.
19. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999;10(Suppl. 4):170-6.
20. Akerstrom G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 2005;19:819-30. (Pubitemid 41614126)
21. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113(Suppl. 7):1807-43.
22. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome.AmJ Surg Pathol 2006;30:560-74. (Pubitemid 44265008)
23. Rindi G, Bordi C. Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract Res Clin Gastroenterol 2005;19:519-34.
24. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-40. (Pubitemid 26076883)
25. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev 2005;26:615-61. (Pubitemid 41127274)
26. Hessman O, Skogseid B, Westin G, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 2001;86:1355-61. (Pubitemid 32323028)
27. D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999;79:671-7. (Pubitemid 29283420)
28. Debelenko LV, Emmert-Buck MR, Manickam P, Kester M, Guru SC, DiFranco EM, et al. Haplotype analysis defines a minimal interval for the multiple endocrine neoplasia type 1 (MEN1) gene. Cancer Res 1997;57:1039-42. (Pubitemid 27138596)
29. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682-6. (Pubitemid 27468966)
30. Goebel SU, Heppner C, Burns AL, Marx SJ, Spiegel AM, Zhuang Z, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 2000;85:116-23. (Pubitemid 32268800)
31. Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001;32:177-81.
32. Woodward ER, Maher ER. Von Hippel-Lindau disease and endocrine tumour susceptibility. Endocr Relat Cancer 2006;13:415-25. (Pubitemid 43886666)
33. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. Front Horm Res 2001;28:131-66. (Pubitemid 33816385)
34. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel- Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-95.
35. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-67. (Pubitemid 36695052)
36. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 1998;153:223-31. (Pubitemid 28317525)
37. Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar A, Frazier M, et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002;62:1952-5. (Pubitemid 34408436)
38. Alexakis N, Connor S, Ghaneh P, Lombard M, Smart HL, Evans J, et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004;4:417-33 (discussion: 34-5).
39. Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000;128:1022-7 (discussion: 7-8).
40. Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 1991;101:465-71.
41. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997;100:404-10. (Pubitemid 27349088)
42. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7. (Pubitemid 27274517)
43. Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995;59:67-73.
44. Nesi G, Marcucci T, Rubio CA, Brandi ML, Tonelli F. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J Gastroenterol Hepatol 2008;23:521-6. (Pubitemid 351501140)
45. Trovo-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet 2006;70:1-13. (Pubitemid 44192729)
46. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005;102:8573-8. (Pubitemid 40862777)
47. van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998;7:1053-7. (Pubitemid 28256600)
48. Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli FM, Giannotti A, Dominici C, et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003;27:1386-9. (Pubitemid 37185831)
49. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 2002;8:109-12. (Pubitemid 34248088)
50. McLean A. Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging 2004;4:84-91.
51. Giovannini M. Contrast-enhanced and 3-dimensional endoscopic ultrasonography. Gastroenterol Clin North Am 2010;39:845-58.
52. Badea R, Seicean A, Diaconu B, Stan-Iuga R, Sparchez Z, Tantau M, et al. Contrast-enhanced ultrasound of the pancreas - a method beyond its potential or a new diagnostic standard? J Gastrointestin Liver Dis 2009;18:237-42.
53. Rickes S, Unkrodt K, Ocran K, Neye H, Wermke W. Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy. Pancreas 2003;26:76-81. (Pubitemid 36020270)
54. D'Onofrio M, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging 2004;29:246-58. (Pubitemid 38365018)
55. Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216:163-71. (Pubitemid 30434737)
56. Van Hoe L, Gryspeerdt S, Marchal G, Baert AL, Mertens L. Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. AJR Am J Roentgenol 1995;165:1437-9.
57. Fidler JL, Fletcher JG, Reading CC, Andrews JC, Thompson GB, Grant CS, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003;181:775-80. (Pubitemid 37021854)
58. Buetow PC, Parrino TV, Buck JL, Pantongrag-Brown L, Ros PR, Dachman AH, et al. Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR Am J Roentgenol 1995;165:1175-9.
59. Bordeianou L, Vagefi PA, Sahani D, Deshpande V, Rakhlin E, Warshaw AL, et al. Cystic pancreatic endocrine neoplasms: a distinct tumor type? J Am Coll Surg 2008;206:1154-8.
60. Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 2006;187:W472-80.
61. Semelka RC, Custodio CM, Cem Balci N, Woosley JT. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11:141-8. (Pubitemid 30080967)
62. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and longterm survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711-9.
63. Simon P, Spilcke-Liss E, Wallaschofski H. Endocrine tumors of the pancreas. Endocrinol Metab Clin North Am 2006;35:431-47, xii.
64. Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003;181:987-92. (Pubitemid 37151778)
65. Power N, Reznek RH. Imaging pancreatic islet cell tumours. Imaging 2002;14:147-59. (Pubitemid 351649418)
66. Sheth S, Hruban RK, Fishman EK. Helical CT of islet cell tumors of the pancreas: typical and atypical manifestations. AJR Am J Roentgenol 2002;179:725-30. (Pubitemid 34919589)
67. Howard TJ, Stabile BE, Zinner MJ, Chang S, Bhagavan BS, Passaro E Jr. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1990;159:258-64. (Pubitemid 20057932)
68. Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO, Wiedenmann B. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000;62(Suppl. 1):45-50. (Pubitemid 30665939)
69. Ruttman E, Kloppel G, Bommer G, Kiehn M, Heitz PU. Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature. Virchows Arch A Pathol Anat Histol 1980;388:51-67. (Pubitemid 10032412)
70. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995;80:2273-8.
71. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 1981;76:125-31. (Pubitemid 12234879)
72. Eelkema EA, Stephens DH, Ward EM, Sheedy PF 2nd. CT features of nonfunctioning islet cell carcinoma. AJR Am J Roentgenol 1984;143:943-8. (Pubitemid 15207713)
73. Jani N, Khalid A, Kaushik N, Brody D, Bauer K, Schoedel K, et al. EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. Gastrointest Endosc 2008;67:44-50. (Pubitemid 350266630)
74. Imhof H, Frank P. Pancreatic calcifications in malignant islet cell tumors. Radiology 1977;122:333-7. (Pubitemid 8028943)
75. Semelka RC, Cumming MJ, Shoenut JP, Magro CM, Yaffe CS, Kroeker MA, et al. Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 1993;186:799-802. (Pubitemid 23073525)
76. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 2010;22:381-6.
77. Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73. (Pubitemid 36418403)
78. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16:219-24. (Pubitemid 46206635)
79. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007;12:253-70. (Pubitemid 46953565)
80. Hobday TJ, Mahoney M, Erlichman C, Lloyd R, Kim G, Mulkerin D, Picus J, et al. Preliminary results of a phase II trial of Gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II Consortium (PC2) study. Proc Am Soc Clin Oncol 2005;23:328s.
81. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007;21:163-72. (Pubitemid 46421905)
82. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007;18:1307-13.
83. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.
84. Yao JC, Phan AT, Chang DZ, Jacobs C, Mares JE, Rashid A, et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2006;24(18S):4042.
85. Duran I, Le L, Saltman D, Singh D, Kocha W, Cheiken R, eds. A phase II trial of temsirolimus in metastatic neuroendocrine tumors. Proceedings of 2005 Gastrointestinal Cancers Symposium. Chicago, IL: American Society of Clinical Oncology; 2005.